Featured news from NHIVNA
HIV-related news from NAM
AbbVie 3D regimen and sofosbuvir/ribavirin show high cure rates for HCV in people with HIV co-infection
Liz Highleyman, 2014-11-21 09:20:00
AbbVie's 3D regimen (paritaprevir/ombitasvir/ritonavir plus dasabuvir) with ribavirin for 12 weeks and Gilead Science's sofosbuvir (Sovaldi) plus ribavirin for 24 weeks both produced good sustained virological response rates for most people with HIV and hepatitis C virus (HCV) co-infection, according to studies presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting last week in Boston, United States.
People with HIV and HCV co-infection tend to experience more rapid liver disease progression and traditionally were considered more difficult to treat using interferon-based therapy than people with HCV mono-infection. With the advent of all-oral direct-acting antiviral regimens, however, a growing body of evidence indicates that people with co-infection have response rates similar to those of people with hepatitis C alone.
Source:1
